Steroid–tacrolimus drug–drug interaction and the effect of CYP3A genotypes

• Published in: British journal of clinical pharmacology Vol. 90; no. 11; pp. 2837 - 2848
• Main Authors: Saqr, Abdelrahman, Al‐Kofahi, Mahmoud, Mohamed, Moataz, Dorr, Casey, Remmel, Rory P., Onyeaghala, Guillaume, Oetting, William S., Guan, Weihua, Mannon, Roslyn B., Matas, Arthur J., Israni, Ajay, Jacobson, Pamala A.
• Format: Journal Article
• Language: English
• Published: England 01.11.2024
• Subjects: CYP3A; interaction; kidney transplantation; pharmacogenomics; Shiny app; steroids; tacrolimus; CYP3A; pharmacogenomics; Shiny app; tacrolimus; kidney transplantation; interaction; steroids
• ISSN: 0306-5251; 1365-2125; 1365-2125
• DOI: 10.1111/bcp.16172

Aims Tacrolimus, metabolized by CYP3A4 and CYP3A5 enzymes, is susceptible to drug–drug interactions (DDI). Steroids induce CYP3A genes to increase tacrolimus clearance, but the effect is variable. We hypothesized that the extent of the steroid–tacrolimus DDI differs by CYP3A4/5 genotypes. Methods Kidney transplant recipients (n = 2462) were classified by the number of loss of function alleles (LOF) (CYP3A5*3, *6 and *7 and CYP3A4*22) and steroid use at each tacrolimus trough in the first 6 months post‐transplant. A population pharmacokinetic analysis was performed by nonlinear mixed‐effect modelling (NONMEM) and stepwise covariate modelling to define significant covariates affecting tacrolimus clearance. A stochastic simulation was performed and translated into a Shiny application with the mrgsolve and Shiny packages in R. Results Steroids were associated with modestly higher (3%–11.8%) tacrolimus clearance. Patients with 0‐LOF alleles receiving steroids showed the greatest increase (11.8%) in clearance compared to no steroids, whereas those with 2‐LOFs had a negligible increase (2.6%) in the presence of steroids. Steroid use increased tacrolimus clearance by 5% and 10.3% in patients with 1‐LOF and 3/4‐LOFs, respectively. Conclusions Steroids increase the clearance of tacrolimus but vary slightly by CYP3A genotype. This is important in individuals of African ancestry who are more likely to carry no LOF alleles, may more commonly receive steroid treatment, and will need higher tacrolimus doses.